Tivic Health Systems (NASDAQ:TIVC) Director Christina Rizopoulos Valauri Buys 19,000 Shares of Stock

Tivic Health Systems, Inc. (NASDAQ:TIVC) Director Christina Rizopoulos Valauri bought 19,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $18,050.00. Following the completion of the transaction, the director owned 19,000 shares of the company’s stock, valued at $18,050. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Tivic Health Systems Stock Down 1.0%

Tivic Health Systems stock opened at $1.00 on Friday. The business has a 50 day moving average price of $0.93 and a two-hundred day moving average price of $1.76. Tivic Health Systems, Inc. has a 12 month low of $0.72 and a 12 month high of $13.23. The stock has a market cap of $1.77 million, a price-to-earnings ratio of -0.15 and a beta of 1.84.

Tivic Health Systems (NASDAQ:TIVC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($408.00) by $406.97. Tivic Health Systems had a negative return on equity of 202.20% and a negative net margin of 1,557.26%.

Hedge Funds Weigh In On Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Marex Group plc bought a new position in shares of Tivic Health Systems, Inc. (NASDAQ:TIVC) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 39,283 shares of the company’s stock, valued at approximately $163,000. Marex Group plc owned approximately 3.64% of Tivic Health Systems as of its most recent SEC filing. 4.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tivic Health Systems in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Tivic Health Systems

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.